Impact BioMedical is not a biopharmaceutical company that happens to be small. It is a Nevada science-licensing shell with a handful of polyphenol platforms, a near-empty treasury, and no commercial revenue engine. The single fact that defines the stock right now is structural rather than scientific. On September 14 of the current year, the company announced a reverse stock split that becomes effective late in the month, paired with a proposed one-for-one merger with Zoar Limited, formerly Dr. Ashley's Limited, that has not yet closed. The equity is being asked to underwrite a listing-compliance maneuver and an unannounced corporate combination at the same time.
The most recent quarterly filing shows the cash position that makes the maneuver necessary. Stockholders' equity sits at roughly ten and three-quarter million, yet the cash and cash-equivalents balance is essentially zero at the period close, having collapsed from about two million a year earlier. The company is staying solvent on related-party support and on a capital structure it reshaped by converting a large related-party note into tens of millions of shares during the fourth quarter of the prior year. Revenue for the quarter was a few thousand units.
That is the tension to hold in mind. The reverse split compresses the share count from about 107.8 million to roughly 8.5 million, and the pending merger would hand Impact holders one share of Zoar for each post-split share they hold. The question the next several months resolve is whether the Zoar transaction and the NYSE American compliance cure are real enough to support a market cap that currently prices the whole enterprise in the tens of millions, against a business with no meaningful cash and no product revenue.